Drawing for CREATIVE BIOMART RECOMBINANT PROTEINS

USPTO serial 87066966

CREATIVE BIOMART RECOMBINANT PROTEINS

Reviewed by CopyMark Law Group

Reg. 5136522Status 710
Filing date
Status date
Registration date
Feb 7, 2017
Examiner
BODRI, KRISTIN MARIE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with CREATIVE BIOMART RECOMBINANT PROTEINS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David Lin

1330 Avenue of the Americas14th FloorNew York, NY 10019

Goods and services

ClassDescriptionStatusFirst use
042Bacteriological consultation and research; Bacteriological research and testing; Biochemical research and development; Biological research; Biomedical research services; Biotechnology research; Chemical analysis; Chemical engineering; Chemical laboratories; Chemical research; Chemical, biochemical, biological and bacteriological research and analysis; Chemist services; Chemistry consultation; Compiling data for research purposes in the field of medical science and medical consultancy; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Custom design and development of chemical reagents and biochemical assays; Design and testing of new products for others; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Development and test of chemical production methods; Development of pharmaceutical preparations and medicines; DNA analysis services for scientific research purposes; Drug discovery services; Executing of chemical analyses; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Laboratory analysis in the field of bacteriology, chemistry, and cosmetics; Laboratory research services relating to pharmaceuticals; Laboratory services, namely, pigment and color analysis; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research information in the field of drug discovery; Medical laboratory services; Medical research; Medical research services in the field of cancer; Performance of chemical analyses; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Product testing; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; Research and development in the field of drug discovery; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of new products for others; Research and development of technology in the field of drug discovery; Research in the field of chemistry; Research on the subject of pharmaceuticals; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of drug discovery, medicine, the prevention, treatment and management of illness, health care delivery, and cancerous diseases; Scientific research in the field of genetics and genetic engineeringSECTION 8 - CANCELLEDJan 1, 2006

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 18, 2023C8..CANCELLED SEC. 8 (6-YR)—
Feb 7, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Oct 8, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 7, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 22, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 22, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 2, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 15, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 15, 2016ALIEASSIGNED TO LIE—
Sep 29, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 27, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Sep 27, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 27, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 27, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 21, 2016DOCKASSIGNED TO EXAMINER—
Jun 18, 2016MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 17, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 14, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance